The Pathogenesis and Therapeutic Implications of Tubulointerstitial Inflammation in Human Lupus Nephritis

Semin Nephrol. 2015 Sep;35(5):455-64. doi: 10.1016/j.semnephrol.2015.08.007.


Nephritis is a common complication of systemic lupus erythematosus for which current therapies often prove inadequate. Current lupus nephritis classification systems emphasize glomerular acuity and scarring. However, tubulointerstitial inflammation (TII) and scarring are much better predictors of progression to renal failure. It now is becoming clear that the immunologic features, and probable underlying mechanisms, are very different in lupus glomerulonephritis and TII at the time of biopsy. Although glomerulonephritis is a manifestation of systemic autoimmunity, TII is associated with local in situ adaptive immune cell networks predicted to amplify local inflammation and tissue damage. In addition, poorly defined networks of innate immune cells and effectors likely contribute to the severity of local inflammation. Defining these in situ immune mechanisms should lead to a better understanding of prognostically meaningful lupus nephritis subsets and show novel therapeutic opportunities.

Keywords: Lupus nephritis; adaptive immunity; innate immunity; tubulointerstitial inflammation.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Adaptive Immunity / immunology
  • Autoimmunity / immunology*
  • Glomerulonephritis / drug therapy
  • Glomerulonephritis / immunology
  • Glomerulonephritis / pathology
  • Humans
  • Immunity, Innate / immunology
  • Immunosuppressive Agents / therapeutic use
  • Inflammation
  • Kidney / immunology*
  • Kidney / pathology
  • Lupus Nephritis / drug therapy
  • Lupus Nephritis / immunology*
  • Lupus Nephritis / pathology
  • Nephritis, Interstitial / drug therapy
  • Nephritis, Interstitial / immunology*
  • Nephritis, Interstitial / pathology


  • Immunosuppressive Agents